Top

Published in:

Open Access 01-12-2024 | Invasive Aspergillosis | Research

Age difference of patients with and without invasive aspergillosis: a systematic review and meta-analysis

Authors: Elena Shekhova, Fabián Salazar, Alessandra Da Silva Dantas, Tanmoy Chakraborty, Eva L. Wooding, P. Lewis White, Adilia Warris

Published in: BMC Infectious Diseases | Issue 1/2024

Abstract

Background

Invasive Aspergillosis (IA) is a life-threatening fungal disease with significant mortality rates. Timely diagnosis and treatment greatly enhance patient outcomes. This study aimed to explore the association between patient age and the development of IA, as well as the potential implications for risk stratification strategies.

Methods

We searched National Center for Biotechnology Information (NCBI) databases for publications until October 2023 containing age characteristics of patients with and without IA. A random-effects model with the application of inverse-variance weighting was used to pool reported estimates from each study, and meta-regression and subgroup analyses were utilized to assess sources of heterogeneity.

Results

A systematic review was conducted, resulting in the inclusion of 55 retrospective observational studies with a total of 13,983 patients. Meta-analysis revealed that, on average, patients with IA were approximately two and a half years older (95% Confidence Interval [CI] 1.84–3.31 years; I² = 26.1%) than those without the disease (p < 0.0001). No significant moderators could explain the observed heterogeneity in age difference. However, subgroup analysis revealed that age differences were more pronounced within particular patient groups compared to others. For example, patients with and without IA who had primary severe lung infections exhibited a greater difference in mean age than other patient cohorts.

Conclusions

Further research, such as individual patient data meta-analysis, is necessary to better understand the potential relationship between increasing age and the likelihood of IA. Improved risk stratification strategies based on patient age could potentially enhance the early detection and treatment of IA, ultimately improving patient outcomes.

Available only for authorised users

Arastehfar A, Carvalho A, Houbraken J, Lombardi L, Garcia-Rubio R, Jenks JD, et al. Aspergillus Fumigatus and aspergillosis: from basics to clinics. Studies in Mycology. CBS-KNAW Fungal Biodiversity Centre. 2021. https://doi.org/10.1016/j.simyco.2021.100115.CrossRef

Brown GD, Denning DW, Gow NAR, Levitz SM, Netea MG, White TC. Hidden killers: human fungal infections. Sci Transl Med. 2012. https://doi.org/10.1126/scitranslmed.3004404.CrossRefPubMedPubMedCentral

Herbrecht R, Bories P, Moulin JC, Ledoux MP, Letscher-Bru V. Risk stratification for invasive aspergillosis in immunocompromised patients. Ann N Y Acad Sci. 2012. https://doi.org/10.1111/j.1749-6632.2012.06829.x.CrossRefPubMed

Latgé JP, Chamilos G. Aspergillus Fumigatus and aspergillosis in 2019. Clin Microbiol Rev. 2020;33. https://doi.org/10.1128/CMR.00140-18.

Schneider JL, Rowe JH, Garcia-de-Alba C, Kim CF, Sharpe AH, Haigis MC. The aging lung: physiology, disease, and immunity. Cell. 2021;184:1990–2019. https://doi.org/10.1016/j.cell.2021.03.005.

Mattos CT, de Ruellas AC. O Evidence-based Orthod. 2015. https://doi.org/10.1590/2176-9451.20.1.017..

Donnelly JP, Chen SC, Kauffman CA, Steinbach WJ, Baddley JW, Verweij PE, the Mycoses Study Group Education and Research Consortium. Revision and update of the Consensus definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer and. Clin Infect Dis. 2020;71:1367–76. https://doi.org/10.1093/cid/ciz1008.CrossRefPubMed

Blot SI, Taccone FS, Van Den Abeele AM, Bulpa P, Meersseman W, Brusselaers N, et al. A clinical algorithm to diagnose Invasive Pulmonary aspergillosis in critically ill patients. Am J Respir Crit Care Med. 2012;186:56–64. https://doi.org/10.1164/rccm.201111-1978OC.CrossRefPubMed

Lajeunesse MJ. Facilitating systematic reviews, data extraction and meta-analysis with the metagear package for R. Methods Ecol Evol. 2016;7:323–30. https://doi.org/10.1111/2041-210X.12472.CrossRef

10.

Viechtbauer W. Conducting Meta-analyses in R with the metafor Package. J Stat Softw. 2010;36:1–48. https://doi.org/10.18637/jss.v036.i03.CrossRef

11.

Lin Pedersen Thomas. patchwork: The Composer of Plots. 2021.

12.

Harrer M, Cuijpers P, Furukawa T, Ebert DD. dmetar: Companion R Package For The Guide Doing Meta-Analysis in R. 2019. Available: http://dmetar.protectlab.org/..

13.

Wickham H, François R, Henry L, Müller K. dplyr: A grammar of data manipulation. R package version 1.0.6. 2021.

14.

Wickham H. ggplot2: Elegant Graphics for Data Analysis. Springer-Verlag New York; 2016. Available: https://ggplot2.tidyverse.org..

15.

Balduzzi S, Rücker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health. 2019;22:153–60. https://doi.org/10.1136/ebmental-2019-300117.CrossRefPubMedPubMedCentral

16.

Gohel David. flextable: Functions for Tabular Reporting. R package version 0.6.9. https://CRAN.R-project.org/package=flextable.. 2021.

17.

Luo D, Wan X, Liu J, Tong T. Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. Stat Methods Med Res. 2018;27:1785–805. https://doi.org/10.1177/0962280216669183.MathSciNetCrossRefPubMed

18.

Shi J, Luo D, Weng H, Zeng XT, Lin L, Chu H, et al. Optimally estimating the sample standard deviation from the five-number summary. Res Synth Methods. 2020;11:641–54. https://doi.org/10.1002/jrsm.1429.CrossRefPubMed

19.

Viechtbauer W. Bias and Efficiency of Meta-Analytic Variance Estimators in the Random-Effects Model. J Educ Behav Stat. 2005;30(3):261–93. https://doi.org/10.3102/10769986030003261.CrossRef

20.

Viechtbauer W. Confidence intervals for the amount of heterogeneity in meta-analysis. Stat Med. 2007;26:37–52. https://doi.org/10.1002/sim.2514.MathSciNetCrossRefPubMed

21.

Knapp G, Hartung J. Improved tests for a random effects meta-regression with a single covariate. Stat Med. 2003;22:2693–710. https://doi.org/10.1002/sim.1482.CrossRefPubMed

22.

Viechtbauer W, Cheung MW-L. Outlier and influence diagnostics for meta-analysis. Res Synth Methods. 2010;1:112–25. https://doi.org/10.1002/jrsm.11.CrossRefPubMed

23.

Harrer M, Cuijpers P, Ebert AFT. Doing Meta-analysis with R: a Hands-On Guide. 1st ed. Boca Raton: Chapman & Hall/CRC; 2021.CrossRef

24.

Baujat B, Mahé C, Pignon JP, Hill C. A graphical method for exploring heterogeneity in meta-analyses: application to a meta-analysis of 65 trials. Stat Med. 2002;21:2641–52. https://doi.org/10.1002/sim.1221.CrossRefPubMed

25.

Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34. https://doi.org/10.1136/bmj.315.7109.629.CrossRefPubMedPubMedCentral

26.

Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995;273(5):408–412. https://doi.org/10.1001/jama.273.5.408.

27.

Palmer TM, Peters JL, Sutton AJ, Moreno SG. Contour-enhanced funnel plots for meta-analysis. Stata J. 2008. Available: http://www.stata.com/support/faqs/stat/meta.html..

28.

Wells GA, Wells G, Shea B, Shea B, O’Connell D, Peterson J et al. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses. 2014. Available: https://api.semanticscholar.org/CorpusID:79550924..

29.

Levesque E, Ait-Ammar N, Dudau D, Clavieras N, Feray C, Foulet F, et al. Invasive pulmonary aspergillosis in cirrhotic patients: analysis of a 10-year clinical experience. Ann Intensive Care. 2019;9:9. https://doi.org/10.1186/s13613-019-0502-2.CrossRef

30.

Michallet M, Sobh M, Morisset S, Kraghel S, Nicolini FE, Thomas X, et al. Risk factors for invasive aspergillosis in acute myeloid leukemia patients prophylactically treated with posaconazole. Med Mycol. 2011;49:681–7. https://doi.org/10.3109/13693786.2011.557668.CrossRefPubMed

31.

Napolioni V, Pariano M, Borghi M, Oikonomou V, Galosi C, De Luca A, et al. Genetic polymorphisms affecting IDO1 or IDO2 activity differently associate with aspergillosis in humans. Front Immunol. 2019;10:10. https://doi.org/10.3389/fimmu.2019.00890.CrossRef

32.

Mikulska M, Raiola AM, Bruno B, Furfaro E, Van Lint MT, Bregante S, et al. Risk factors for invasive aspergillosis and related mortality in recipients of allogeneic SCT from alternative donors: an analysis of 306 patients. Bone Marrow Transpl. 2009;44:361–70. https://doi.org/10.1038/bmt.2009.39.CrossRef

33.

White PL, Parr C, Barnes RA. Predicting Invasive Aspergillosis in Hematology Patients by Combining Clinical and Genetic Risk Factors with Early Diagnostic Biomarkers. J Clin Microbiol. 2017;56(1):e01122-17. https://doi.org/10.1128/JCM.01122-17.

34.

Michallet M, Bénet T, Sobh M, Kraghel S, El Hamri M, Cannas G, et al. Invasive aspergillosis: an important risk factor on the short- and long-term survival of acute myeloid leukemia (AML) patients. Eur J Clin Microbiol Infect Dis. 2012;31:991–7. https://doi.org/10.1007/s10096-011-1397-5.CrossRefPubMed

35.

Lahmer T, Brandl A, Rasch S, Baires GB, Schmid RM, Huber W, et al. Prevalence and outcome of invasive pulmonary aspergillosis in critically ill patients with liver cirrhosis: an observational study. Sci Rep. 2019;9:9. https://doi.org/10.1038/s41598-019-48183-4.CrossRef

36.

Waldeck F, Boroli F, Suh N, Wendel Garcia PD, Flury D, Notter J, et al. Influenza-associated aspergillosis in critically-ill patients—a retrospective bicentric cohort study. Eur J Clin Microbiol Infect Dis. 2020;39:1915–23. https://doi.org/10.1007/s10096-020-03923-7.CrossRefPubMedPubMedCentral

37.

Chen L, Han X, Li Y, Zhang C, Xing X. Invasive pulmonary aspergillosis in immunocompetent patients hospitalised with influenza A-related pneumonia: a multicenter retrospective study. BMC Pulm Med. 2020;20:20. https://doi.org/10.1186/s12890-020-01257-w.CrossRef

38.

Luong ML, Chaparro C, Stephenson A, Rotstein C, Singer LG, Waters V, et al. Pretransplant aspergillus colonization of cystic fibrosis patients and the incidence of post-lung transplant invasive aspergillosis. Transplantation. 2014;97:351–7. https://doi.org/10.1097/01.TP.0000437434.42851.d4.CrossRefPubMed

39.

Chauvet P, Mallat J, Arumadura C, Vangrunderbeek N, Dupre C, Pauquet P, et al. Risk factors for Invasive Pulmonary aspergillosis in critically ill patients with Coronavirus Disease 2019-Induced Acute Respiratory Distress Syndrome. Crit Care Explor. 2020;2:e0244. https://doi.org/10.1097/cce.0000000000000244.CrossRefPubMedPubMedCentral

40.

Kurosaki F, Bando M, Nakayama M, Mato N, Nakaya T, Yamasawa H, et al. Clinical features of pulmonary aspergillosis associated with interstitial pneumonia. Intern Med. 2014;53:1299–306. https://doi.org/10.2169/internalmedicine.53.1578.CrossRefPubMed

41.

Dellière S, Dudoignon E, Fodil S, Voicu S, Collet M, Oillic PA, et al. Risk factors associated with COVID-19-associated pulmonary aspergillosis in ICU patients: a French multicentric retrospective cohort. Clin Microbiol Infect. 2021;27:790e1-7790. https://doi.org/10.1016/j.cmi.2020.12.005.CrossRef

42.

Bellelli V, Siccardi G, Conte L, Celani L, Congeduti E, Borrazzo C, et al. Preliminary attempt to predict risk of invasive pulmonary aspergillosis in patients with influenza: decision trees may help? Antibiotics. 2020;9:1–8. https://doi.org/10.3390/antibiotics9100644.CrossRef

43.

Tejerina EE, Abril E, Padilla R, Rodríguez Ruíz C, Ballen A, Frutos-Vivar F, et al. Invasive aspergillosis in critically ill patients: an autopsy study. Mycoses. 2019;62:673–9. https://doi.org/10.1111/myc.12927.CrossRefPubMed

44.

Razazi K, Arrestier R, Haudebourg AF, Benelli B, Carteaux G, Decousser JW, et al. Risks of ventilator-associated pneumonia and invasive pulmonary aspergillosis in patients with viral acute respiratory distress syndrome related or not to Coronavirus 19 disease. Crit Care. 2020;24. https://doi.org/10.1186/s13054-020-03417-0.

45.

Heylen L, Maertens J, Naesens M, Wijngaerden E, Van, Lagrou K, Bammens B et al. Invasive Aspergillosis after Kidney Transplantation: Case-Control Study. 2015. Available: http://cid.oxfordjournals.org/..

46.

Seok H, Huh K, Young Cho S, Kang C-I, Ryeon Chung D, Seong Huh W et al. Risk factors for development and mortality of invasive pulmonary aspergillosis in kidney transplantation recipients. https://doi.org/10.1007/s10096-020-03871-2/Published..

47.

Kaya S, Gençalioǧlu E, Sönmez M, Köksal I. The importance of risk factors for the prediction of patients with invasive pulmonary aspergillosis. Rev Assoc Med Bras. 2017;63:764–70. https://doi.org/10.1590/1806-9282.63.09.764.CrossRefPubMed

48.

Bitterman R, Hardak E, Raines M, Stern A, Zuckerman T, Ofran Y et al. Baseline chest computed tomography for early diagnosis of Invasive Pulmonary aspergillosis in Hemato-oncological Patients-a prospective cohort study. https://doi.org/10.1093/cid/ciz194/5373534..

49.

Chen J, Yang Q, Huang J, Li L. Risk factors for invasive pulmonary aspergillosis and hospital mortality in acute-on-chronic liver failure patients: a retrospective-cohort study. Int J Med Sci. 2013;10:1625–31. https://doi.org/10.7150/ijms.6824.CrossRefPubMedPubMedCentral

50.

López-Medrano F, Fernández-Ruiz M, Silva JT, Carver PL, van Delden C, Merino E, et al. Multinational case-control study of risk factors for the development of late invasive pulmonary aspergillosis following kidney transplantation. Clin Microbiol Infect. 2018;24:192–8. https://doi.org/10.1016/j.cmi.2017.06.016.CrossRefPubMed

51.

Rodriguez-Goncer I, Thomas S, Foden P, Richardson MD, Ashworth A, Barker J, et al. Invasive pulmonary aspergillosis is associated with adverse clinical outcomes in critically ill patients receiving veno-venous extracorporeal membrane oxygenation. Eur J Clin Microbiol Infect Dis. 2018;37:1251–7. https://doi.org/10.1007/s10096-018-3241-7.CrossRefPubMedPubMedCentral

52.

Herrera S, Gohir W, Foroutan F, Aguilar C, Juvet S, Martinu T, et al. Cytokine profile in lung transplant recipients with aspergillus spp colonization. Transpl Infect Disease. 2019;21:e13060. https://doi.org/10.1111/tid.13060.CrossRef

53.

Nagao M, Fujimoto Y, Yamamoto M, Matsumura Y, Kaido T, Takakura S, et al. Epidemiology of invasive fungal infections after liver transplantation and the risk factors of late-onset invasive aspergillosis. J Infect Chemother. 2016;22:84–9. https://doi.org/10.1016/j.jiac.2015.11.005.CrossRefPubMed

54.

Wauters J, Baar I, Meersseman P, et al. Invasive pulmonary aspergillosis is a frequent complication of critically ill H1N1 patients: a retrospective study. Intensive Care Med. 2012;38(11):1761–8. https://doi.org/10.1007/s00134-012-2673-2.CrossRefPubMedPubMedCentral

55.

Garnacho-Montero J, Amaya-Villar R, Ortiz-Leyba C, León C, Alvarez-Lerma F, Nolla-Salas J, et al. Isolation of aspergillus spp. from the respiratory tract in critically ill patients: risk factors, clinical presentation and outcome. Crit Care. 2005;9. https://doi.org/10.1186/cc3488.

56.

Sharma A, Mishra T, Kumar N, Soubani AO. Influenza-associated aspergillosis: nationwide trends, predictors and outcomes from 2005 to 2014. Chest. 2020;158:1857–66. https://doi.org/10.1016/j.chest.2020.06.010.CrossRefPubMed

57.

Huang L, Zhang N, Huang X, Xiong S, Feng Y, Zhang Y, et al. Invasive pulmonary aspergillosis in patients with influenza infection: a retrospective study and review of the literature. Clin Respiratory J. 2019;13:202–11. https://doi.org/10.1111/crj.12995.CrossRef

58.

Robin C, Cordonnier C, Sitbon K, Raus N, Lortholary O, Maury S, et al. Mainly post-transplant factors are Associated with Invasive aspergillosis after allogeneic stem cell transplantation: a study from the Surveillance Des Aspergilloses invasives en France and Société Francophone De Greffe De Moelle Et de Thérapie Cellulaire. Biol Blood Marrow Transplant. 2019;25:354–61. https://doi.org/10.1016/j.bbmt.2018.09.028.CrossRefPubMed

59.

Zhang X, Yang M, Hu J, Zhao H, Li L. Epidemiology of invasive pulmonary aspergillosis in patients with liver failure: clinical presentation, risk factors, and outcomes. J Int Med Res. 2018;46:819–27. https://doi.org/10.1177/0300060517729907.CrossRefPubMed

60.

Cook JC, Cook A, Tran RH, Chang PP, Rodgers JE. A case-control study of the risk factors for developing aspergillosis following cardiac transplant. Clin Transpl. 2018;32. https://doi.org/10.1111/ctr.13367.

61.

Xu H, Li L, Huang WJ, Wang LX, Li WF, Yuan WF. Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: a case control study from China. Clin Microbiol Infect. 2012;18:403–8. https://doi.org/10.1111/j.1469-0691.2011.03503.x.CrossRefPubMed

62.

Zou P, Wang C, Zheng S, Guo F, Yang L, Zhang Y, et al. Invasive pulmonary aspergillosis in adults with avian influenza a (H7N9) pneumonia in China: a retrospective study. J Infect Dis. 2020;221:193-S197. https://doi.org/10.1093/INFDIS/JIZ682.CrossRef

63.

Muñoz P, Rodríguez C, Bouza E, Palomo J, Yañez JF, Domínguez MJ, et al. Risk factors of invasive aspergillosis after heart transplantation: protective role of oral itraconazole Prophylaxis. Am J Transplant. 2004;4:636–43. https://doi.org/10.1111/j.1600-6143.2004.00390.x.CrossRefPubMed

64.

Fukuda T, Boeckh M, Guthrie KA, Mattson DK, Owens S, Wald A, et al. Invasive aspergillosis before allogeneic hematopoietic stem cell transplantation: 10-year experience at a single transplant center. Biol Blood Marrow Transplant. 2004;10:494–503. https://doi.org/10.1016/j.bbmt.2004.02.006.CrossRefPubMed

65.

López-Medrano F, Silva JT, Fernández-Ruiz M, Carver PL, van Delden C, Merino E, et al. Risk factors Associated with Early Invasive Pulmonary aspergillosis in kidney transplant recipients: results from a multinational matched case–control study. Am J Transplant. 2016;16:2148–57. https://doi.org/10.1111/ajt.13735.CrossRefPubMed

66.

Hahn T, Cummings KM, Michalek AM, Lipman BJ, Segal BH, McCarthy PL. Efficacy of high-efficiency Particulate Air Filtration in preventing aspergillosis in immunocompromised patients with hematologic malignancies. Infect Control Hosp Epidemiol. 2002;23:525–31. https://doi.org/10.1086/502101.CrossRefPubMed

67.

Thursky K, Byrnes G, Grigg A, Szer J, Slavin M. Risk factors for post-engraftment invasive aspergillosis in allogeneic stem cell transplantation. Bone Marrow Transpl. 2004;34:115–21. https://doi.org/10.1038/sj.bmt.1704543.CrossRef

68.

Gustot T, Maillart E, Bocci M, Surin R, Trépo E, Degré D, et al. Invasive aspergillosis in patients with severe alcoholic hepatitis. J Hepatol. 2014;60:267–74. https://doi.org/10.1016/j.jhep.2013.09.011.CrossRefPubMed

69.

Mühlemann K, Wenger C, Zenhäusern R, Täuber MG. Risk factors for invasive aspergillosis in neutropenic patients with hematologic malignancies. Leukemia. 2005;19:545–50. https://doi.org/10.1038/sj.leu.2403674.CrossRefPubMed

70.

Schwarzinger M, Sagaon-Teyssier L, Cabaret O, Bretagne S, Cordonnier C. Performance of serum biomarkers for the early detection of invasive aspergillosis in febrile, neutropenic patients: a multi-state model. PLoS ONE. 2013;8:e65776. https://doi.org/10.1371/journal.pone.0065776.CrossRefPubMedPubMedCentralADS

71.

Kontoyiannis DP, Chamilos G, Lewis RE, Giralt S, Cortes J, Raad II, et al. Increased bone marrow iron stores is an independent risk factor for invasive aspergillosis in patients with high-risk hematologic malignancies and recipients of allogeneic hematopoietic stem cell transplantation. Cancer. 2007;110:1303–6. https://doi.org/10.1002/cncr.22909.CrossRefPubMed

72.

Kim SH, Hong JY, Bae S, Lee H, Wi YM, Ko JH, et al. Risk factors for Coronavirus Disease 2019 (COVID-19)-Associated Pulmonary aspergillosis in critically ill patients: a Nationwide, Multicenter, Retrospective Cohort Study. J Korean Med Sci. 2022;37. https://doi.org/10.3346/jkms.2022.37.e134..

73.

Gu Y, Ye X, Liu Y, Wang Y, Shen K, Zhong J, et al. A risk-predictive model for invasive pulmonary aspergillosis in patients with acute exacerbation of chronic obstructive pulmonary disease. Respir Res. 2021;22:22. https://doi.org/10.1186/s12931-021-01771-3.CrossRef

74.

Er B, Er AG, Gülmez D, Şahin TK, Halaçlı B, Durhan G, et al. A screening study for COVID-19-associated pulmonary aspergillosis in critically ill patients during the third wave of the pandemic. Mycoses. 2022;65:724–32. https://doi.org/10.1111/myc.13466.CrossRefPubMedPubMedCentral

75.

Le Pavec J, Pradère P, Gigandon A, Dauriat G, Dureault A, Aguilar C, et al. Risk of Lung Allograft Dysfunction Associated with aspergillus infection. Transpl Direct. 2021;7:E675. https://doi.org/10.1097/TXD.0000000000001128.CrossRef

76.

Calderón-Parra J, Mills-Sanchez P, Moreno-Torres V, Tejado-Bravo S, Romero-Sánchez I, Balandin-Moreno B, et al. COVID-19-associated pulmonary aspergillosis (CAPA): risk factors and development of a predictive score for critically ill COVID-19 patients. Mycoses. 2022;65:541–50. https://doi.org/10.1111/myc.13434.CrossRefPubMedPubMedCentral

77.

Xu Y, Shao M, Liu N, Tang J, Gu Q, Dong D. Invasive pulmonary aspergillosis is a frequent complication in patients with severe fever with thrombocytopenia syndrome: a retrospective study. Int J Infect Dis. 2021;105:646–52. https://doi.org/10.1016/j.ijid.2021.02.088.CrossRefPubMed

78.

de Almeida JN, Doi AM, Watanabe MJL, Maluf MM, Calderon CL, Silva M, et al. COVID-19-associated aspergillosis in a Brazilian referral centre: diagnosis, risk factors and outcomes. Mycoses. 2022;65:449–57. https://doi.org/10.1111/myc.13433.CrossRefPubMedPubMedCentral

79.

Lahmer T, Kriescher S, Herner A, Rothe K, Spinner CD, Schneider J, et al. Invasive pulmonary aspergillosis in critically ill patients with severe COVID-19 pneumonia: results from the prospective AspCOVID-19 study. PLoS One. 2021;16: e0238825. https://doi.org/10.1371/journal.pone.0238825.CrossRefPubMedPubMedCentral

80.

Song L, Zhao Y, Wang G, Zou W, Sai L. Investigation of predictors for invasive pulmonary aspergillosis in patients with severe fever with thrombocytopenia syndrome. Sci Rep. 2023;13:13. https://doi.org/10.1038/s41598-023-28851-2.CrossRef

81.

Waldeck F, Boroli F, Zingg S, Walti LN, Wendel-Garcia PD, Conen A, et al. Higher risk for influenza-associated pulmonary aspergillosis (IAPA) in asthmatic patients: a Swiss multicenter cohort study on IAPA in critically ill influenza patients. Influenza Other Respir Viruses. 2023;17. https://doi.org/10.1111/irv.13059.

82.

Dai Y, Pu Q, Hu N, Zhu J, Han Y, Shi P, et al. The dose–response relationship between smoking and the risk factor for invasive pulmonary aspergillosis in patients with severe fever with thrombocytopenia syndrome. Front Microbiol. 2023;14:14. https://doi.org/10.3389/fmicb.2023.1209705.CrossRef

83.

van Grootveld R, van der Beek MT, Janssen NAF, Ergün M, van Dijk K, Bethlehem C, et al. Incidence, risk factors and pre-emptive screening for COVID-19 associated pulmonary aspergillosis in an era of immunomodulant therapy. J Crit Care. 2023;76:154272. https://doi.org/10.1016/j.jcrc.2023.154272.CrossRefPubMedPubMedCentral

84.

Chao CM, Lai CC, Ou HF, Ho CH, Chan KS, Yang CC, et al. The impacts of aspergillosis on outcome, burden and risks for mortality in influenza patients with critical illness. J Fungi. 2021;7. https://doi.org/10.3390/jof7110922.

85.

Prattes J, Wauters J, Giacobbe DR, Salmanton-García J, Maertens J, Bourgeois M, et al. Risk factors and outcome of pulmonary aspergillosis in critically ill coronavirus disease 2019 patients—a multinational observational study by the European Confederation of Medical Mycology. Clin Microbiol Infect. 2022;28:580–7. https://doi.org/10.1016/j.cmi.2021.08.014.CrossRefPubMed

86.

Hurt W, Youngs J, Ball J, Edgeworth J, Hopkins P, Jenkins DR, et al. COVID-19-associated pulmonary aspergillosis in mechanically ventilated patients: a prospective, multicentre UK study. Thorax. BMJ Publishing Group; 2023. https://doi.org/10.1136/thorax-2023-220002.

87.

Janssen NAF, Nyga R, Vanderbeke L, Jacobs C, Ergün M, Buil JB, et al. Multinational observational cohort study of covid-19-associated pulmonary aspergillosis1. Emerg Infect Dis. 2021;27:2892–8. https://doi.org/10.3201/eid2711.211174.CrossRefPubMedPubMedCentral

88.

Bentvelsen RG, Van Arkel ALE, Rijpstra TA, Kant MKM, Brugge SVDS, Van Der, Loth DW, et al. Regional Impact of COVID-19-Associated pulmonary aspergillosis (CAPA) during the First Wave. J Fungi. 2022;8. https://doi.org/10.3390/jof8020096.

89.

Katada Y, Nakagawa S, Nagao M, Yoshida Y, Matsuda Y, Yamamoto Y, et al. Risk factors of breakthrough aspergillosis in lung transplant recipients receiving itraconazole prophylaxis. J Infect Chemother. 2022;28:54–60. https://doi.org/10.1016/j.jiac.2021.09.020.CrossRefPubMed

90.

Lee R, Cho SY, Lee DG, Ahn H, Choi H, Choi SM, et al. Risk factors and clinical impact of COVID-19-associated pulmonary aspergillosis: multicenter retrospective cohort study. Korean J Intern Med. 2022;37:851–63. https://doi.org/10.3904/kjim.2022.069.CrossRefPubMedPubMedCentral

91.

Apostolopoulou A, Clancy CJ, Skeel A, Nguyen MH. Invasive pulmonary aspergillosis complicating Noninfluenza respiratory viral infections in solid organ transplant recipients. Open Forum Infect Dis. 2021;8. https://doi.org/10.1093/ofid/ofab478.

92.

Feys S, Lagrou K, Lauwers HM, Haenen K, Jacobs C, Brusselmans M, et al. High burden of COVID-19-associated pulmonary aspergillosis (CAPA) in severely immunocompromised patients requiring mechanical ventilation. Clin Infect Dis. 2023. https://doi.org/10.1093/cid/ciad546.CrossRefPubMedCentral

93.

Dubler S, Etringer M, Weigand MA, Brenner T, Zimmermann S, Schnitzler P, et al. Impact of Invasive Pulmonary aspergillosis in critically Ill Surgical patients with or without solid organ transplantation. J Clin Med. 2023;12:3282. https://doi.org/10.3390/jcm12093282.CrossRefPubMedPubMedCentral

94.

Pérez-Jacoiste Asín MA, López-Medrano F, Fernández-Ruiz M, Silva JT, San Juan R, Kontoyiannis DP, et al. Risk factors for the development of invasive aspergillosis after kidney transplantation: systematic review and meta-analysis. Am J Transplant. 2021;21:703–16. https://doi.org/10.1111/ajt.16248.CrossRefPubMed

95.

Chong WH, Saha BK, Neu KP. Comparing the clinical characteristics and outcomes of COVID-19-associate pulmonary aspergillosis (CAPA): a systematic review and meta-analysis. Infection. 2022;50:43–56. https://doi.org/10.1007/s15010-021-01701-x.CrossRefPubMed

96.

Fabián S, Elaine B, D BG, C CP, Adilia W. Pathogenesis of respiratory viral and fungal coinfections. Clin Microbiol Rev. 2021;35:e00094-00021. https://doi.org/10.1128/CMR.00094-21.CrossRef

97.

Lei Y, Guerra Martinez C, Torres-Odio S, Bell SL, Birdwell CE, Bryant JD, et al. Elevated type I interferon responses potentiate metabolic dysfunction, inflammation, and accelerated aging in mtDNA mutator mice. Sci Adv. 2023;7:eabe7548. https://doi.org/10.1126/sciadv.abe7548.CrossRefADS

98.

D’Souza SS, Zhang Y, Bailey JT, Fung ITH, Kuentzel ML, Chittur SV, et al. Type I Interferon signaling controls the accumulation and transcriptomes of monocytes in the aged lung. Aging Cell. 2021;20:20. https://doi.org/10.1111/acel.13470.CrossRef

99.

Gil L, Kozlowska-Skrzypczak M, Mol A, Poplawski D, Styczynski J, Komarnicki M. Increased risk for invasive aspergillosis in patients with lymphoproliferative diseases after autologous hematopoietic SCT. Bone Marrow Transpl. 2009;43:121–6. https://doi.org/10.1038/bmt.2008.303.CrossRef

100.

Wald A, Leisenring W, Van Burik JA, Bowden RA. Epidemiology of aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis. 1997;175:1459–66. https://doi.org/10.1086/516480.CrossRefPubMed

101.

Taccone FS, Van den Abeele AM, Bulpa P, Misset B, Meersseman W, Cardoso T, et al. Epidemiology of invasive aspergillosis in critically ill patients: clinical presentation, underlying conditions, and outcomes. Crit Care. 2015;19:1–15. https://doi.org/10.1186/s13054-014-0722-7.CrossRef

102.

Sun KS, Tsai CF, Chen SCC, Huang WC. Clinical outcome and prognostic factors associated with invasive pulmonary aspergillosis: an 11-year follow-up report from Taiwan. PLoS ONE. 2017;12. https://doi.org/10.1371/journal.pone.0186422..

103.

Matthaiou DK, Dimopoulos G, Taccone FS, Bulpa P, Van Den Abeele AM, Misset B, et al. Elderly versus nonelderly patients with invasive aspergillosis in the ICU: a comparison and risk factor analysis for mortality from the AspICU cohort. Med Mycol. 2018;56:668–78. https://doi.org/10.1093/mmy/myx117.CrossRefPubMed

104.

Christensen H, May M, Bowen L, Hickman M, Trotter CL. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10:853–61. https://doi.org/10.1016/S1473-3099(10)70251-6.CrossRefPubMed

105.

Thorlacius-Ussing L, Sandholdt H, Larsen AR, Petersen A, Benfield T. Age-dependent increase in incidence of Staphylococcus aureus Bacteremia, Denmark, 2008–2015. Emerg Infect Dis. 2019;25:875–82. https://doi.org/10.3201/eid2505.181733.CrossRefPubMedPubMedCentral

Title: Age difference of patients with and without invasive aspergillosis: a systematic review and meta-analysis
Authors: Elena Shekhova
Fabián Salazar
Alessandra Da Silva Dantas
Tanmoy Chakraborty
Eva L. Wooding
P. Lewis White
Adilia Warris
Publication date: 01-12-2024
Publisher: BioMed Central
Keywords: Invasive Aspergillosis
Aspergillosis
Published in: BMC Infectious Diseases / Issue 1/2024
Electronic ISSN: 1471-2334
DOI: https://doi.org/10.1186/s12879-024-09109-2

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2024

Development and clinical application of loop-mediated isothermal amplification combined with lateral flow assay for rapid diagnosis of SARS-CoV-2

Bacterial infections in patients with COVID-19: the impact of procalcitonin testing on antibiotics prescription in the real world

Severe pneumonia with H5N1 and SARS-CoV-2 co-infection

Global prevalence and burden of multidrug-resistant tuberculosis from 1990 to 2019

Chronic disseminated candidiasis in a patient with acute leukemia - an illustrative case and brief review for clinicians

Enhancing enteric pathogen detection: implementation and impact of multiplex PCR for improved diagnosis and surveillance

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage